ImageneBio(NASDAQ) IMA

Market Cap$64.18M

Since IPO (2025)-65%

5 Year-95%

1 Year-61%

1 Month-4%

$5.66

+0.53%

+0.03Today

After hours$5.58-$0.08 (-1.41%)

ImageneBio last closing stock price
Metric	Price	Date
Last close	USD 5.69	2026-08-07

ImageneBio stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+2.71%	USD 5.54	2026-07-31
1 month	-3.97%	USD 5.93	2026-07-08
3 month	+7.56%	USD 5.29	2026-05-08
Year to date	-17.54%	USD 6.90	2025-12-31
1 year	-61.29%	USD 14.70	2025-08-07
3 year	-89.15%	USD 52.44	2023-08-08
5 year	-95.43%	USD 124.44	2021-08-06
Since inception	-65.24%	USD 16.37	2025-07-28

ImageneBio Financials at a Glance

Market Cap

$64.18M

Revenue (TTM)

$0.00

Net Income (TTM)

-$52.48M

EPS (TTM)

-$5.20

P/E Ratio

-1.09

Dividend

$0.00

Beta (Volatility)

1.10 (Average)

Dividend

$0.00

Beta (Volatility)

1.10 (Average)

Price

$5.66

Volume

32,305.44

Open

$5.60

Price

$5.66

Volume

32,305.44

Open

$5.60

Previous Close

$5.69

Daily Range

$5.32 - $5.79

52-Week Range

$3.94 - $15.27

Estimated Earnings Date

Nov 11, 2026

Dividend

$0.00

Beta (Volatility)

1.10 (Average)

Price

$5.66

Volume

32,305.44

Open

$5.60

Previous Close

$5.69

Daily Range

$5.32 - $5.79

52-Week Range

$3.94 - $15.27

Estimated Earnings Date

Nov 11, 2026

IMA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ImageneBio

ImageneBio develops medicines for people with immune system diseases. Its main drug aims to help those with skin and inflammatory conditions. The company focuses on treatments that may improve daily life for patients with chronic illnesses.

What’s in the ImageneBio Toolbox?

IMG-007: Experimental antibody drug for immune and inflammatory diseases, targeting patients with atopic dermatitis and similar conditions.
Licensing Revenue: Income from agreements to use company technology, representing all reported revenue.
Research & Development Services: Uses third-party partners for drug development and manufacturing, serving clinical trial needs.

Growth and Expansion: ImageneBio’s Plot Twists

Completed merger with Ikena Oncology in July 2025, expanding resources and pipeline focus.
Divested non-OX40 assets in July 2025 to concentrate on IMG-007.
Secured exclusive global license for IMG-007 from Hutchmed (excluding cancer uses).
Raised $75 million in PIPE financing and $54.6 million from merger in 2025.
Expanded clinical trial sites beyond North America in 2025 to support global studies.

What Makes ImageneBio Stand Out?

ImageneBio focuses on a single, engineered antibody drug with potential for several immune diseases. Its approach aims to reduce side effects by not destroying immune cells. The company relies on global partners for manufacturing and clinical development.

Five Things You Need to Know

Revenue was $0 in QQ3 2025, down 100% from QQ3 2023.
Net loss was $27 million in QQ3 2025, down 114.3% from QQ3 2024.
Operating loss was $25 million in QQ3 2025, down 142.1% from QQ3 2024.
Cash used in operations was $27 million in QQ3 2025, down 198.1% from QQ3 2024.

Bottom Line

ImageneBio has narrowed its focus to one main drug and relies on partnerships for growth. The company faces ongoing losses but maintains a clear strategy in immune disease treatment.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Kristin Yarema, PhD

Website

www.inmagenebio.com

Headquarters

San Diego, CA 92130, US

IMA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-38.99%

Return on Capital

-33.85%

Return on Assets

-34.52%

Earnings Yield

-91.74%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$64.18M

Shares Outstanding

11.28M

Volume

32.31K

Avg. Volume

19.27K

Financials (TTM)

Gross Profit

-$735.00K

Operating Income

-$58.96M

EBITDA

-$52.80M

Operating Cash Flow

-$73.38M

Capital Expenditure

$0.00

Free Cash Flow

-$73.38M

Cash & ST Invst.

$136.15M

Total Debt

$1.91M

ImageneBio Performance Analysis

ImageneBio annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 15,618,000	-49.6%
2023	2023-12-31	USD 9,160,000	-41.3%
2024	2024-12-31	USD 3,500,000	-61.8%
2025	2025-12-31	USD 800,000	-77.1%

ImageneBio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A
Q2	2026-06-30	N/A

ImageneBio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -22.80	100.4%
2023	2023-12-31	USD -19.60	-14.0%
2024	2024-12-31	USD -40.52	106.7%
2025	2025-12-31	USD -9.64	-76.2%

ImageneBio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-5153.1%
Q4	2025-12-31	79.4%
Q1	2026-03-31	-53.2%
Q2	2026-06-30	33.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$64.18M

N/A

Market Cap/Employee

$4.28M

N/A

Employees

N/A

Net Income

-$10.18M

-267.8%

EBITDA

-$9.81M

-17.5%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$136.15M

+42.4%

Total Debt

$1.91M

-66.3%

Accounts Receivable

$2.56M

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$1.91M

-50.1%

Return on Assets

-34.52%

N/A

Return on Invested Capital

-40.53%

N/A

Free Cash Flow

-$24.72M

-622.4%

Operating Cash Flow

-$24.72M

-622.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

KLRSKalaris Therapeutics Inc

KLRSKalaris Therapeutics Inc$4.07-2.86%

MGXMetagenomi, Inc. Common Stock

MGXMetagenomi, Inc. Common Stock$1.23-0.81%

CNTXContext Therapeutics Inc.

CNTXContext Therapeutics Inc.$0.48-3.97%

QNCXQuince Therapeutics, Inc.

QNCXQuince Therapeutics, Inc.$30.20+2.23%

IFRXInflaRx N.V.

IFRXInflaRx N.V.$1.84+6.98%

CNTBConnect Biopharma Holdings Limited

CNTBConnect Biopharma Holdings Limited$2.21+0.68%

STROSutro Biopharma, Inc.

STROSutro Biopharma, Inc.$25.38+5.09%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$133.11+0.16%

TTDThe Trade Desk

TTDThe Trade Desk$13.80-0.22%

NVDANvidia

NVDANvidia$223.96+0.02%

TLTiShares Trust - iShares 20+ Year Treasury Bond ETF

TLTiShares Trust - iShares 20+ Year Treasury Bond ETF$82.76+0.00%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$8.11+0.06%

PLTRPalantir Technologies

PLTRPalantir Technologies$172.01+0.10%

INTCIntel

INTCIntel$101.65+0.02%

Questions About IMA

What is the current price of ImageneBio?

ImageneBio is trading at $5.69 per share.

What is the 52-week range for ImageneBio?

Over the past 52 weeks, ImageneBio has traded between $3.94 and $15.27.

How much debt does ImageneBio have?

As of the most recent reporting period, ImageneBio reported total debt of $4.47M.

How much cash does ImageneBio have on hand?

ImageneBio reported $94.68M in cash and cash equivalents in its most recent financial results.

What is ImageneBio’s dividend yield?

ImageneBio does not currently have a dividend yield.

ImageneBio(NASDAQ) IMA

ImageneBio Financials at a Glance

IMA News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About ImageneBio

What’s in the ImageneBio Toolbox?

Growth and Expansion: ImageneBio’s Plot Twists

What Makes ImageneBio Stand Out?

Five Things You Need to Know

Bottom Line

IMA Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

ImageneBio Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About IMA

What is the current price of ImageneBio?

What is the 52-week range for ImageneBio?

How much debt does ImageneBio have?

How much cash does ImageneBio have on hand?

What is ImageneBio’s dividend yield?

Premium Investing Services